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1. Introduction 
The fl-adrenergic receptor on the turkey erythrocyte 
was shown to couple with the adenylate cyclase 
system of the Friend erythroleukemia cell when the 
membranes of the two cells are fused with each other 
by Sendai virus f 1 ]. Prior to cell fusion the adenylate 
cyclase system in the turkey erythrocyte was 
irreversibly inactivated by ~~~y~~eirnide (NEM) 
or by heat so that this cell could contribute only the 
hormone receptor but not the enzyme. The work was 
subsequently extended to hybridize the P-adrenergic 
receptor and also the prostaglandin El receptor with 
adenylate cyclase systems of various types of cultured 
cells [2]. These experiments suggested that the 
receptors tested exist in the cell membrane as inde- 
pendent units which freely dissociate from the 
adenylate cyclase system and that receptors and 
enzyme, ori~nating from various tissues and from 
different anima! species, are compatible with each 
other in forming a functional complex. However, 
these conclusions were based only on testing the 
receptors for two hormones of low molecular weight. 
Receptors for the much larger and structurally 
different molecules, the peptide hormones, might 
have rather different properties. It had, for instance, 
been demonstrated that receptors for peptide hor- 
mones are quite susceptible to trypsin while the 
fi-adrenergic receptor in the same cells was not [3]. 
Because of these con~derations and because of the 
great physiolo~cal importance of the peptide 
hormones, it seemed essential to learn whether their 
receptors too are freely transferable to the adenylate 
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cyclase system of other cells. For this purpose a cell 
line originating from a human colon carcinoma 
(HT29) [4], possessing a receptor [5] for the vaso- 
active intestinal peptide hormone (VIP) was chosen. 
This cell line has been shown in studies of hormone 
binding to possess aconsiderable number of VIP 
receptors and to respond to VIP with a dramatic 
increase in the level of intracellular cyclic AMP [5,6]. 
Thus the HT29 cell seemed to fulfill the prerequisites 
for an attempt o transfer the receptor for a peptide 
hormone. 
It should be noted that VIP is a well-defined hor- 
mone of known sequence [7], which has been 
prepared also synthetically [8]. It is found at high 
concentration i  the gut but recently was also located 
in brain cortex and hypothalamus [9]. VIP receptors 
were characterized inpancreas [5,10,1 l], gut [12], 
liver [ 13,141, fat cells [14] and in the HT29 cell line 
E61. 
2. Materials and methods 
For the current experiments cultures of HT29 
were grown in Roux glass bottles for 6-8 days at 
37°C in Dulbecco’s modified Eagle medium con- 
taining 10% fetal calf serum. The cells were suspended 
by treating 3 min with crystalline proteases as in [*2]. 
To terminate proteolysis [2] ~-methylsulfonyl 
fluoride, lo-’ M was added together with soybean 
trypsin inhibitor, 1 mg/ml. The protease inhibitors 
were added at all subsequent s eps of preparation of 
the HT29 cell suspension. The cells were washed and 
41 
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suspended in Na’medium [2]. Aliquots were treated 
with 5 mM NEM for 10 min at 4°C to inactivate the 
adenylate cyclase [ 11. Five volumes of 14 mM mer- 
captoethanol were subsequently added at 0°C. The 
suspension was kept 3 min at 0°C followed by 10 min 
at 25’C. After centrifugation the cells were suspended 
in Na+ medium. 
Growth of T3C12 Friend erythroleukemia (Fc) 
cells [l] and their fusion with HT29 cells was per- 
formed as in [2]. Activation of adenylate cyclase by 
VIP was measured after cell fusion on cell ghosts 
prepared by hypotonic lysis [ 11. 
3. Results and discussion 
Fifteen experiments of fusion of NEM-treated 
HT29 cells with Fc cells were performed. In all 
experiments there was a definite enhancement of 
adenylate cyclase activity due to the addition of VIP 
to the assay system. The increase in rate ranged from 
2-5-fold over the basal activity. A representative 
experiment is shown in fig. 1. 
Controls of Fc cells fused with each other or of 
NEM-treated HT29 cells did not show any stimulation 
of adenylate cyclase by VIP. Fc cells were also 
checked for specific VIP binding and none was 
detected. It can therefore be concluded that the 
activation of adenylate cyclase by VIP after fusion of 
NEM-treated HT29 cells with Fc cells is due to the 
transfer of the VIP receptor to the adenylate cyclase 
system of the other cell. The affinity of the receptor 
for VIP seems not to change when it is transferred to 
the heterologous adenylate cyclase of the Fc cells 
(table 1). The same observation holds with regard to 
Table 1 
Hormone concentration producing half maximal activation 
of adenylate cyclase in fused cell membranes 
Cells in fusion VIP Secretin 
(nM) (nM) 
HT29-HT29 3 2000 
HT29 NEM-FC 2 1000 
Fusion systems were prepared as in fig.1. Adenylate cyclase 
activities were determined on cell ghosts in the presence of 
various hormone concentrations. The half maximal concen- 
tration was calculated from a Lineweaver-Burk plot 
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Fig.1. Transfer of the VIP receptor of HT29 cells to the 
adenylate cyclase of Fc cells by cell fusion. Adenylate cyclase 
activities are shown for cell ghosts prepared by hypotonic 
lysis after cell fusion [ 1,2]. Fusion systems were: (I) NEM- 
treated HT29 cells, 1 x 10’ fused with each other by Sendai 
virus, 700 haemagghttinating units (HAU); (II) Fc cells, 
3 X lo6 fused with each other, virus 200 HAU; (III) 
heterologous fusion of HT29 NEM-treated cells, 1.2 X 10’ 
with Fc cells, 3 x lo6 by virus, 1000 HAU; (IV) untreated, 
HT29 cells, 2.2 X lo6 fused with each other by virus, 
200 HAU. The cell types which participate in fusion are 
symbolized in the figure by fused circles in each set of 
columns. At the base of each column the activating agent is 
specified: B, basal activity; porcine VIP, 20 nM in 0.1% 
bovine serum albumin; F, fluoride, 10 mM. The response of 
the hormone receptor transferred to a heterologous ystem is 
emphasized by a hatched column. Adenylate cyclase activities 
shown were measured [151 in duplicate on cell ghosts 
equivalent o 1/7th of the cells in the original fusion system 
above. Incubation was 10 min 37°C. 
the closely-related hormone, secretin, which 
apparently acts on the VIP receptor [5,6,10,1 l] when 
applied at a very high concentration. Thus the 
specificity of the receptor also appears to remain 
unaltered during transfer. 
The experiments clearly show that the receptors 
for a peptide hormone couple to the adenylate 
cyclase of another cell as demonstrated for the 
P-adrenergic and PGEr receptors [ 1,2]. It is therefore 
suggested that the receptors are composed of a 
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~~rrn~ne-rec~~~i~~ part which is higNv specific and 
a constant fragment, common to all these receptors, 
which couples to the adenylate cyclase system. It 
seems quite Iikely that the different hormone receptors 
evolved uring evolution from a common ancestor 
receptor molecule by mutations in the recognition 
site. 
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